The Pulmonary - Critical Care Medicine Branch
(P-CCMB) conducts research related to basic cell and molecular biology,
bench-to-bedside translational research projects, and clinical research on lung
disease. Areas of basic research include cytokine biology, signal transduction
pathways (e.g., nitric oxide, G proteins, cyclic nucleotide
phosphodiesterases), vesicular trafficking, post-translational modification of
proteins (e.g., ADP-ribosylation), and mechanisms of bacterial toxin action.
P-CCMB translational studies use state-of-the-art techniques (e.g., genomics,
proteomics) to define the pathogenesis of lung disease (e.g., asthma, cystic
fibrosis, lymphangioleiomyomatosis (LAM), pulmonary fibrosis, and sarcoidosis).
Areas of active clinical investigation with on-going protocols include: (1)
identification of clinical, pathological, genetic, and physiological criteria
for the determination of disease severity and progression in cystic fibrosis,
LAM, and pulmonary fibrosis, (2) identification of novel therapeutic approaches
for the treatment of lung disease (e.g., asthma and sarcoidosis), (3)
development of new technologies for the prevention of nosocomial pneumonia and
ventilator-induced injury.
Last updated: August 29, 2002 |
PCCMB Dr. Joel Moss,
Chief E-mail: mossj@nhlbi.nih.gov
- Principal Investigators
|